GENE ONLINE|News &
Opinion
Blog

2024-01-24| Trials & Approvals

FDA Boxed Warning for CAR-T therapy, Affecting Bristol-Myers Squibb, Novartis, Janssen, Gilead Sciences

by Oscar Wu
Share To

The US Food and Drug Administration (FDA) required a boxed safety warning for five commercial CAR-T cell therapies from Bristol-Myers Squibb, Novartis, Janssen, Gilead Sciences, on January 19, 2024, due to the risk of secondary T-cell malignancies. Boxed safety warning is the most serious safety alert issued by the agency and highlights the potential risk of “secondary T-cell malignancies” associated with these treatments. Despite these risks, the FDA has not banned the use of CAR-T therapy. Instead, it has reminded manufacturers to include a warning about the risks in their product labeling. This warning is intended to ensure that healthcare professionals and patients are fully aware of the risks before making treatment decisions.

(Resource from FDA, organized by GeneOnline)

What is the risk of secondary T-cell malignancies and why is this a concern?

CAR-T (Chimeric Antigen Receptor T-cell) therapy is a type of immunotherapy that involves genetically modifying a patient’s own T cells to recognize and attack cancer cells. It has shown significant promise in treating certain types of blood cancers, such as leukemia and lymphoma.

The boxed warning emphasizes the risk of developing new cancerous growths of T cells after receiving CAR-T therapy, known as “secondary T-cell malignancies”, which are a group of blood disorders including lymphoma and leukemia. These malignancies can be serious or even fatal, including hospitalization and death, following treatment.

Date back to November 28, 2023, FDA has announced the occurrence of T cell malignancies, including CAR-positive lymphoma, in patients treated with BCMA- or CD19-directed autologous CAR-T cell immunotherapies, raising the awareness of healthcare professionals and patients before making treatment decisions.

Boxed warning alerts to potential risks of CAR-T therapy, calls for medical monitoring

The specific wording of the boxed warning may vary slightly depending on the CAR-T product, but it will generally include the following key points:

  1. T-cell malignancies have occurred following treatment with CAR-T therapy.
  2. These malignancies can be mature T-cell malignancies, including CAR-positive tumors, and may present as early as weeks following infusion.
  3. The malignancies can be fatal.
  4. Patients who receive CAR-T therapy should be monitored for life for the development of new malignancies.

What should you do if you are considering CAR-T therapy?

If you are still considering CAR-T therapy, it is important to discuss the risks and benefits of the treatment with your healthcare professional. You should also be sure to ask about the specific monitoring plan that will be in place to detect any potential development of secondary T-cell malignancies. The decision of whether or not to undergo CAR-T therapy is different between each individual. It is important to weigh the risks and benefits carefully and make an informed decision in consultation with the healthcare professional.

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Author
Related Post
Experts Gather to Explore New Horizons in Health Technology Assessment
2024-09-25
Apple’s AirPods Pro 2: First Ever FDA-approved OTC Hearing Aid Technology
2024-09-20
Biotech Industry Trends in 2024: A Look at the Billions in Oncology Deals
2024-09-18
LATEST
Generative AI Makes its Debut in Smart Healthcare with NVIDIA Experts at the Helm
2024-10-04
TCELS’s Path to a Self-Sufficient Biotech Thailand: Entrepreneurs in Global Competitiveness, Raw Material Exports, and Cosmetic Innovations
2024-10-04
Lilly Invests $4.5B in Indiana Facility for In-House Clinical Manufacturing
2024-10-03
Can New GLP-1 Contenders Disrupt the Weight-Loss Giants, Lilly and Novo, in the Battle for Market Dominance?
2024-10-03
2024 Tang Prize Celebrates Revolutionary Biopharma Discoveries, a Nod to Game-Changing Diabetes and Obesity Treatments
2024-09-30
Eyes on Nvidia: A Strong Investment Prospect, Driving Billions in AI Development and Advanced Infrastructure
2024-09-30
Immunai and AstraZeneca’s $18 Million AI Collaboration to Transform Cancer Drug Development
2024-09-26
EVENT
2024-10-09
Medical Japan 2024 Tokyo
Tokyo, Japan
2024-10-15
BIO Investor Forum 2024
San Francisco, U.S.A.
2024-10-28
BioFuture 2024
New York, U.S.A.
2024-10-30
AusBiotech 2024
Melbourne, Australia
2024-11-04
BIO-Europe 2024
Stockholm, Sweden
Scroll to Top